Poland· PL-100392280

Dupixent

A dupilumab product containing dupilumabum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 16 of our 19 countries.

ATC D11AH05

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about dupilumabumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Dupilumab is registered in 16 of 19 countries.

Countries holding a registration under ATC D11AH05 (dupilumab), each read from that country’s own register.

This record: Poland, from URPL (Poland)
10 of them publish a price we can compare per daily dose

Search dupilumab products by name

Dupilumab · ATC D11AH05

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dupilumab costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Dupilumab · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

CH Switzerland$72.07

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)

Active substance: Dupilumabum
Manufacturer: Sanofi Winthrop Industrie
Country: Poland (PL)
ATC code: D11AH05
ATC class: Dupilumab
Defined daily dose: 21.4 mg, P
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 8

gtin
05909991341381
gtin
05909991341398
gtin
05909991341404
gtin
05909991341411
gtin
05909991341428
gtin
05909991341435
gtin
05909991341442
gtin
05909991341459

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

56 interactions on record for dupilumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check dupilumab against other medicines How interaction checks work

Dupilumab · interactions on record

56 records

27 severe
22 moderate
7 minor

Most severe, free to view

CladribineL01BB04severe
Talimogene laherparepvecL01XL02severe
Talimogen laherparepvecL01XX51severe
LeflunomidL04AA13severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dupilumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dupilumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

United Kingdom (Northern Ireland) · Dupixent
Iceland · Dupixent
Liechtenstein · Dupixent
Norway · Dupixent

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/7681c727-87b9-4a43-9e43-421e0719ce36
GET /v1/drugs/7681c727-87b9-4a43-9e43-421e0719ce36?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "300 mg (150 mg/ml)",
  "packaging": "05909991341381 ¦ Rpz ¦ EU/1/17/1229/001 ¦ 123926\n1 amp.-strzyk. 2 ml\n05909991341398 ¦ Rpz ¦ EU/1/17/1229/002 ¦ 123927\n2 amp.-strzyk. 2 ml\n05909991341404 ¦ Rpz ¦ EU/1/17/1229/003 ¦ 123928\n3 amp.-strzyk. 2 ml\n05909991341411 ¦ Rpz ¦ EU/1/17/1229/004 ¦ 123929\n6 amp.-strzyk. 2 ml\n05909991341428 ¦ Rpz ¦ EU/1/17/1229/005 ¦ 123930\n1 amp.-strzyk. 2 ml z osłonką na igłę\n05909991341435 ¦ Rpz ¦ EU/1/17/1229/006 ¦ 123931\n2 amp.-strzyk. 2 ml z osłonką na igłę\n05909991341442 ¦ Rpz ¦ EU/1/17/1229/007 ¦ 123932\n3 amp.-strzyk. 2 ml z osłonką na igłę\n05909991341459 ¦ Rpz ¦ EU/1/17/1229/008 ¦ 123933\n6 amp.-strzyk. 2 ml z osłonką na igłę",
  "substance": "Dupilumabum 300 mg",
  "common_name": "Dupilumabum",
  "pl_product_id": "100392280",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

API reference MCP server Plans

See everything about dupilumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console